Peptide-based immunoprotection against Rhipicephalus microplus tick

The main agents for tick control are chemical acaricides. However, when used without technical guidance, they can lead to environmental damage and the development of resistant tick strains. In this context, vaccines are alternative o be used in integrated tick management format by combining with other effective tools. We isolated RNA from ticks Rhipicephalus microplus, prepared the library, and performed next-generation sequencing; a pipeline analysis was applied to identify the hypothetical proteins having immunogenic potential and their predicted immunogenic peptides. Twelve peptides, ranging from 12 to 38 amino acid residues, containing the selected epitopes from different targets were selected and synthesized in two forms: the pure peptide; and the peptide conjugated to keyhole limpet hemocyanin (KLH) carrier. These peptides were divided into two groups of six peptides each. The antigen formulations (groups 1 and 2) were prepared with conjugated peptides containing 200 µg of each peptide per dose emulsified with Montanide ISA 61VG (SEPPIC); the control treatment had the adjuvant formulation without peptides (group 3). To evaluate the protective efficacy, 15 weaned male calves (Angus breed) aged around 6 months to one year and weighing approximately 200-250 kg were divided into three groups of five animals each; they were immunized thrice, at an interval of 28 days. After immunization, all the calves infested with 15,000 larvae of Rhipicephalus microplus. Peptide epitopes were recognized by antibodies against host-specific IgGs using indirect ELISA. The mean of the antibody level was determined for each group and compared using analysis of variance with two factors (ANOVA). F-test was used to determine the significance of differences observed between the groups. The percentage efficacy was calculated based on the number of ticks, the weight of teleoginas, and the weight and hatchability of the eggs, compared to that in the control group. The evaluation of immunoprotection indicated efficacies of 69 and 51 %, respectively in Group 1 and 2.